The MatrACELL decellularized dermis process used for ArthroFLEX dermal allografts removes what percentage of donor DNA?

The MatrACELL decellularization process is designed specifically to remove donor DNA from tissue to reduce the risk of immunogenic response when used in grafting procedures, such as with ArthroFLEX dermal allografts. This technique significantly enhances the safety and efficacy of the allograft by lowering the potential for rejection by the recipient’s immune system.

Research indicates that the MatrACELL process achieves a remarkably high level of decellularization, removing more than 97% of the donor's DNA. This extensive removal is critical as DNA can trigger immune responses, which can lead to graft failure. By ensuring such a high percentage of DNA is eliminated, the allografts are not only safer for the recipient but can also promote better integration and healing.

This emphasis on minimizing residual DNA is one of the key selling points for the MatrACELL technology, facilitating better patient outcomes in various surgical applications. While the other percentages listed reflect significant levels of decellularization, they do not reach the threshold of greater than 97%, which is vital in this context.